Webinar: From Uncertainty to Action: Harnessing Industry Leading Variant Classification to Optimize Healthcare Provider Engagement
Thursday, May 22, 2025 at 8:00 am Pacific Time / 11:00 am Eastern Time
Genetic testing has enabled faster and more precise identification of patients who could benefit from new and existing treatments. With robust genomic data, biopharmaceutical companies can better understand the genetic prevalence of rare diseases and collaborate with healthcare providers to increase access to therapeutic options for their patients. Prognos Health and Labcorp, now including Invitae, are jointly committed to enabling life sciences teams to leverage genomic insights to support clinical development and commercialization of potentially life-saving therapies for rare disease patients.
In Part 1 of this webinar series, Prognos and Labcorp will provide an overview of the clinical utility of genetic testing and the opportunities and challenges around variant classification. Labcorp’s innovative approach to resolution of variants of uncertain significance (VUS) reduces uncertainty in genetic testing and provides actionable results to inform patient identification. Join us for Part 1 of this webinar series to learn how to unlock the power of real-world data to accelerate patient access to targeted treatments.
Speakers: Yi-Lee Ting, MS, CGC, Clinical Program Manager, Rare Disease, Labcorp and Andrew Hadd, Director, RWD Product Management, Labcorp
Moderator: Pete Pancione, VP Life Sciences, Prognos Health
Who should attend?
- Commercial leaders (sales and marketing, market research, strategy, medical
and scientific affairs) at biopharma and pharmaceutical organizations
What will be covered in this webinar?
- Leveraging genetic testing data for clinical and commercial use cases
- The complexities around variant classification and how it impacts patient
identification - Labcorp’s innovative approach to minimizing uncertainty in genetic testing
If you are interested in attending please fill out the below form and we will send you a Zoom invitation.
Moderator: Pete Pancione, VP, Life Sciences, Prognos Health
Pete Pancione is the VP of Life Sciences at Prognos Health, bringing over 20 years of experience to the role. He began his career at Accenture, followed by impactful tenures at IMS Health, IQVIA and Lumanity. Pete's expertise lies in harnessing insights from laboratory and other data sources to address the complex challenges faced by pharmaceutical companies in both commercial and RWE domains. He's passionate about supporting commercial strategy by leveraging data-driven insights. Pete resides in Nashville, TN with his wife and children.
Speaker: Yi-Lee Ting, Clinical Program Manager, Rare Disease, Labcorp
Yi-Lee Ting MS, CGC is a clinical program manager at Labcorp. She is responsible for research and collaborations within the rare disease space. She is a board-certified genetic counselor with clinical experience in cardiology, neurology and ophthalmology. Her research interests include the integration of genetic information into clinical care and patient outcomes following genetic testing.
Speaker: Andrew Hadd, Director, RWD Product Management, Labcorp
Andrew Hadd is the director, RWD Product Management at Labcorp, where he oversees commercial product strategy, strategic partnerships and go-to-market activities. He focuses on the genetic & clinical data business supporting partnerships with biopharma, healthtech, health systems and patient advocacy. He came to Labcorp via the Invitae acquisition in the summer of 2024. Andrew previously led the partner management team for Invitae's somatic oncology division, where he supported biopharma clinical trials utilizing minimal residual disease technologies. He previously spent time in academic medical center innovation offices supporting early-stage technology commercialization and startup company formation for therapeutic and diagnostic technology development. Andrew started his career in medical genetics within a clinical diagnostic lab, building out the portfolio of gene panels and clinical exome for rare diseases. He has a PhD in biochemistry from Oregon Health & Science University.